Page 2 - Edication Pricing News Today

An influential US drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals/CRISPR Therapeutics and bluebird bio for sickle cell disease.

Three organizations on Wednesday said they were suing the US government to block enforcement of a program that gives Medicare the power to negotiate drug prices.

The US Chamber of Commerce on Friday sued the federal government, challenging a new law that for the first time gives Medicare the power to negotiate drug prices with pharmaceutical companies.

Leaders of major insulin makers and pharmacy benefit managers traded blame for the life-saving drugs high price while testifying at a US Senate committee hearing.

Vertex Pharmaceuticals and CRISPR Therapeuticss one-dose gene editing therapy for sickle cell disease would be cost effective if priced at up to $1.9 million, an influential US drug pricing group said on Wednesday.

The US government will select the 10 costliest prescription medicines to Medicare for negotiating prices with drugmakers starting early next year, the programs top official said on Friday.

The US health department proposed on Tuesday three new pilot projects aimed at lowering prescription drug prices for people enrolled in government health insurance plans.

The US government will begin imposing penalties in 2025 on drug companies that charge its Medicare program prices that rise faster than inflation, the Centers for Medicare & Medicaid Services said on Thursday.

When Ignasi Biosca-Reig heard there were shortages of amoxicillin in Spain, he quickly added shifts at his drug companys factories to boost production of the popular antibiotic. But a few extra shifts was as far as he could go.

US President Joe Biden will call for a nationwide cap of $35 a month on out-of-pocket insulin costs during his State of the Union Address on Tuesday, but is unlikely to get his wish as it lacks enough Congressional support.